Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9732154B2 · kind B2 · utility
19Cited by
6References
16Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Feb 24, 2015 |
| Grant date | Aug 15, 2017 |
| Priority date | — |
| Expiry date | Feb 24, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/734
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to combination therapies with anti-CD38 antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.